SG11201908179UA - Aryl cyclopropyl-amino-isoquinolinyl amide compounds - Google Patents
Aryl cyclopropyl-amino-isoquinolinyl amide compoundsInfo
- Publication number
- SG11201908179UA SG11201908179UA SG11201908179UA SG11201908179UA SG 11201908179U A SG11201908179U A SG 11201908179UA SG 11201908179U A SG11201908179U A SG 11201908179UA SG 11201908179U A SG11201908179U A SG 11201908179UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- diseases
- amide compounds
- amino
- march
- Prior art date
Links
- -1 Aryl cyclopropyl-amino-isoquinolinyl amide compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- FFOJQAHRRRVYER-UHFFFAOYSA-N (3-cyclopropylisoquinolin-1-yl)hydrazine Chemical class C1CC1C2=CC3=CC=CC=C3C(=N2)NN FFOJQAHRRRVYER-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 235000013365 dairy product Nutrition 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 abstract 1
- YZDXFUGIDTUCDA-UHFFFAOYSA-N isoquinoline-1-carboxamide Chemical class C1=CC=C2C(C(=O)N)=NC=CC2=C1 YZDXFUGIDTUCDA-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480239P | 2017-03-31 | 2017-03-31 | |
| US201862643131P | 2018-03-14 | 2018-03-14 | |
| PCT/US2018/025494 WO2018183911A1 (en) | 2017-03-31 | 2018-03-30 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201908179UA true SG11201908179UA (en) | 2019-10-30 |
Family
ID=63678156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201908179U SG11201908179UA (en) | 2017-03-31 | 2018-03-30 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Country Status (11)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3828172A1 (en) | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| CA2905089C (en) | 2013-03-15 | 2023-06-13 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds for the treatment of ocular diseases |
| BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
| CA3057872A1 (en) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| US11382881B2 (en) | 2017-05-05 | 2022-07-12 | Nino Sorgente | Methods and compositions for diagnosing and treating glaucoma |
| US10780068B2 (en) | 2017-05-05 | 2020-09-22 | Nino Sorgente | Methods and compositions for improving eye health |
| WO2020056345A1 (en) * | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| WO2020176579A1 (en) * | 2019-02-26 | 2020-09-03 | Aerie Pharmaceuticals, Inc. | Thienyl cyclopropyl-amino-isoquinolinyl amide compounds |
| WO2021050994A1 (en) * | 2019-09-13 | 2021-03-18 | Aerie Pharmaceuticals, Inc. | Heterobicyclic carboxamides and uses thereof |
| CN113072538B (zh) * | 2020-01-06 | 2024-04-05 | 广东东阳光药业股份有限公司 | RORγt抑制剂及其在药物中的应用 |
| WO2021207486A1 (en) * | 2020-04-08 | 2021-10-14 | Aerie Pharmaceuticals, Inc. | Treatments |
| US20240336638A1 (en) * | 2021-07-01 | 2024-10-10 | Guoqin ZHUGE | Imidazole compound, and intermediate and application thereof |
| CN115677676B (zh) * | 2022-10-19 | 2024-10-01 | 黑龙江中医药大学 | 一种治疗银屑病的药物及其制备方法 |
Family Cites Families (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2623228C3 (de) | 1976-05-24 | 1981-09-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide |
| JPS5587771A (en) | 1978-12-27 | 1980-07-02 | Teikoku Hormone Mfg Co Ltd | 1-phenylisoquinoline derivative |
| US4456757A (en) | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| JPS5993054A (ja) | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
| DK8386A (da) | 1986-01-15 | 1987-07-09 | Tpo Pharmachim | Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme |
| EP0266949B1 (en) | 1986-10-28 | 1990-11-28 | Smith Kline & French Laboratories Limited | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane a2 antagonists |
| US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5591887A (en) | 1987-04-30 | 1997-01-07 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| JPH01139528A (ja) | 1987-11-24 | 1989-06-01 | Showa Denko Kk | 抗潰瘍剤 |
| EP1348437A3 (en) | 1988-09-06 | 2003-11-19 | Pharmacia Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| ES2075082T3 (es) | 1989-03-28 | 1995-10-01 | Nisshin Flour Milling Co | Derivados de isoquinolina para el tratamiento del glaucoma o hipertension ocular. |
| KR920008026A (ko) | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 |
| WO1993018028A1 (en) | 1992-03-12 | 1993-09-16 | Smithkline Beecham Plc | Indole derivatives as 5ht1c antagonists |
| US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| DE4332168A1 (de) | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
| US5698733A (en) | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
| WO1998021180A1 (en) | 1995-06-07 | 1998-05-22 | Alcon Laboratories, Inc. | Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy |
| US5814660A (en) | 1995-12-22 | 1998-09-29 | Alcon Laboratories, Inc. | 9-oxa prostaglandin analogs as ocular hypotensives |
| US5866602A (en) | 1995-12-22 | 1999-02-02 | Alcon Laboratories, Inc. | Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
| JP3032302B2 (ja) | 1995-12-22 | 2000-04-17 | アルコン ラボラトリーズ，インコーポレイテッド | 眼圧降下剤としてのプロスタグランジンの置換テトラヒドロフランアナログ |
| US5798380A (en) | 1996-02-21 | 1998-08-25 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| US6586425B2 (en) | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
| ATE221048T1 (de) | 1996-09-17 | 2002-08-15 | Asahi Glass Co Ltd | Fluorierte prostaglandinderivate und medikamente |
| AU5436198A (en) | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
| WO1998021182A2 (en) | 1996-11-12 | 1998-05-22 | Alcon Laboratories, Inc. | Use of cis-δ4 analogs of prostaglandins as ocular hypotensives |
| WO1998021181A2 (en) | 1996-11-12 | 1998-05-22 | Alcon Laboratories, Inc. | 15-fluoro prostaglandins as ocular hypotensives |
| WO1998020881A1 (en) | 1996-11-12 | 1998-05-22 | Alcon Laboratories, Inc | 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension |
| US6172109B1 (en) | 1997-03-07 | 2001-01-09 | Alcon Laboratories, Inc. | 13-Thia prostaglandins for use in glaucoma therapy |
| US6037368A (en) | 1997-05-09 | 2000-03-14 | Mount Sinai School Of Medicine | 8-iso- prostaglandins for glaucoma therapy |
| US5891646A (en) | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| SE9702706D0 (sv) | 1997-07-11 | 1997-07-11 | Pharmacia & Upjohn Ab | Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma |
| WO1999012896A1 (en) | 1997-09-09 | 1999-03-18 | The Procter & Gamble Company | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
| ATE227266T1 (de) | 1997-09-09 | 2002-11-15 | Procter & Gamble | Aromatische c16-c20-substituierte tetrahydro- prostaglandine und ihre verwendung als prostaglandin f agonisten |
| ATE270660T1 (de) | 1997-09-09 | 2004-07-15 | Univ Duke | Aromatische c16-c20-substituierte tetrahydro- prostaglandine verwendbar wie fp agoniste |
| US5877211A (en) | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
| US6232344B1 (en) | 1997-12-22 | 2001-05-15 | Alcon Laboratories, Inc. | 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension |
| WO2000003736A1 (en) | 1998-07-14 | 2000-01-27 | Alcon Laboratories, Inc. | Prostaglandin product |
| TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
| US6720175B1 (en) | 1998-08-18 | 2004-04-13 | The Johns Hopkins University School Of Medicine | Nucleic acid molecule encoding homer 1B protein |
| US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| WO2000071511A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
| WO2000076970A2 (en) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Serine protease inhibitors |
| US6699891B1 (en) | 1999-11-26 | 2004-03-02 | Shionogi & Co., Ltd. | Npyy5 antagonists |
| AU776933B2 (en) | 1999-12-28 | 2004-09-23 | Eisai R&D Management Co., Ltd. | Heterocyclic compounds having sulfonamide groups |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| WO2001056607A1 (fr) | 2000-02-03 | 2001-08-09 | Eisai Co., Ltd. | Inhibiteurs de l'expression de l'integrine |
| US6410566B1 (en) | 2000-05-16 | 2002-06-25 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
| US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
| US6855690B2 (en) | 2000-06-01 | 2005-02-15 | Children's Medical Center Corporation | Methods and compositions for treating ocular disorders |
| US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
| AU1401902A (en) | 2000-10-17 | 2002-04-29 | Applied Research Systems | Pharmaceutically active sulfanilide derivatives |
| US7163800B2 (en) | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
| JP2004523565A (ja) | 2001-03-05 | 2004-08-05 | トランス テック ファーマ，インコーポレイテッド | 治療因子としてのベンゾイミダゾール誘導体 |
| JP4366936B2 (ja) | 2001-04-20 | 2009-11-18 | バイエル コーポレイション | キノリル、イソキノリルまたはピリジル尿素を使用するｒａｆキナーゼの阻害 |
| US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
| DE60320933D1 (de) | 2002-01-10 | 2008-06-26 | Bayer Healthcare Ag | Rho-kinase inhibitoren |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| EP1480954B1 (en) | 2002-02-15 | 2008-12-03 | Glaxo Group Limited | Vanilloid receptor modulators |
| AU2003217870A1 (en) | 2002-03-01 | 2003-09-16 | Pintex Pharmaceuticals, Inc. | Pini-modulating compounds and methods of use thereof |
| DK1482931T3 (da) | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
| US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
| GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| CA2483692A1 (en) | 2002-05-13 | 2003-11-27 | Norak Biosciences, Inc. | Constitutively translocating cell line |
| EP2314299A1 (en) | 2002-08-29 | 2011-04-27 | Santen Pharmaceutical Co., Ltd | Therapeutic agent for glaucoma comprising rho kinase inhibitor and prostaglandin |
| WO2004022753A1 (ja) | 2002-08-30 | 2004-03-18 | Anges Mg, Inc. | アクチン関連新規細胞骨格タンパク質ｌａｃｓ |
| CA2502583A1 (en) | 2002-09-12 | 2004-03-25 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same |
| US7495016B2 (en) * | 2002-10-21 | 2009-02-24 | Irm Llc | Pyrrolidones with anti-HIV activity |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| ES2625341T3 (es) | 2003-06-12 | 2017-07-19 | Astellas Pharma Inc. | Derivado de benzamida o sal del mismo |
| AU2004268621C1 (en) | 2003-08-29 | 2011-08-18 | Exelixis, Inc. | c-Kit modulators and methods of use |
| JP2007507547A (ja) | 2003-10-06 | 2007-03-29 | グラクソ グループ リミテッド | キナーゼ阻害剤としての１，７−二置換アザベンゾイミダゾールの調製 |
| DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
| TWI344961B (en) | 2003-10-15 | 2011-07-11 | Ube Industries | Novel indazole derivative |
| SE0400284D0 (sv) | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
| JP2005227441A (ja) | 2004-02-12 | 2005-08-25 | Konica Minolta Medical & Graphic Inc | 光熱写真画像形成材料 |
| WO2005082890A1 (en) | 2004-02-20 | 2005-09-09 | Smithkline Beecham Corporation | Novel compounds |
| US20080096238A1 (en) | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
| DE102004017438A1 (de) | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
| US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
| US20080125427A1 (en) | 2004-06-17 | 2008-05-29 | Smithkline Beecham Corporation | Novel Inhibitors of Rho-Kinases |
| ES2568506T3 (es) | 2004-06-18 | 2016-04-29 | Tobii Ab | Control ocular de aparato computador |
| NZ552866A (en) | 2004-08-26 | 2010-06-25 | Pfizer | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
| EP1810965A4 (en) | 2004-10-13 | 2009-10-28 | Eisai R&D Man Co Ltd | HYDRAZIDE DERIVATIVES |
| UY29198A1 (es) | 2004-11-09 | 2006-05-31 | Cancer Rec Tech Ltd | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones |
| GB0425026D0 (en) | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
| EP1828169A2 (en) | 2004-12-07 | 2007-09-05 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
| WO2007060028A1 (en) | 2004-12-31 | 2007-05-31 | Gpc Biotech Ag | Napthyridine compounds as rock inhibitors |
| JP2008527007A (ja) | 2005-01-14 | 2008-07-24 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Ｒａｆ−キナーゼ阻害活性を有するシンナミドおよびヒドロシンナミド誘導体 |
| CA2594915A1 (en) * | 2005-01-28 | 2006-08-03 | Irm Llc | Phenyl-substituted pyrrolidones |
| US20090005321A1 (en) | 2005-02-09 | 2009-01-01 | Microbia, Inc. | Phenylazetidinone Derivatives |
| CA2608589A1 (en) | 2005-05-25 | 2006-11-30 | Wyeth | Methods of synthesizing 6-alkylaminoquinoline derivatives |
| WO2007008926A1 (en) | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| WO2007008942A2 (en) | 2005-07-11 | 2007-01-18 | Aerie Pharmaceuticals, Inc. | Phenylamino-acetic acid [1-(pyridin-4-yl)-methylidene]-hydrazide derivatives and related compounds as modulators of g protein-coupled receptor kinases for the treatment of eye diseases |
| WO2007050783A2 (en) | 2005-10-26 | 2007-05-03 | Asahi Kasei Pharma Corporation | Fasudil in combination therapies for the treatment of pulmonary arterial hypertension |
| TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| BRPI0620463A2 (pt) | 2005-12-22 | 2011-11-16 | Alcon Res Ltd | composição farmacêutica oftálmica, compostos, e seus usos |
| AR057252A1 (es) | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
| PE20071177A1 (es) | 2005-12-30 | 2008-01-18 | Novartis Ag | Derivados de 3,5-piridina como inhibidores de renina |
| EP1973910B1 (en) | 2006-01-27 | 2013-06-26 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyrrolo[3,2-c]pyridine-4-one 2-indolinone protein kinase inhibitors |
| JP5476559B2 (ja) | 2006-02-10 | 2014-04-23 | 国立大学法人九州大学 | リン酸化酵素の新規基質ポリペプチド |
| WO2007101204A1 (en) | 2006-02-27 | 2007-09-07 | Alcon Research, Ltd. | Method of treating glaucoma |
| EP1991531A1 (en) | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
| JP2007246466A (ja) | 2006-03-17 | 2007-09-27 | Osaka Univ | 中枢神経損傷に対する嗅粘膜移植にＲｈｏキナーゼ阻害剤を用いた神経機能再建法 |
| WO2007142323A1 (ja) | 2006-06-08 | 2007-12-13 | Ube Industries, Ltd. | 側鎖にスピロ環構造を有する新規インダゾール誘導体 |
| US20080021217A1 (en) | 2006-07-20 | 2008-01-24 | Allen Borchardt | Heterocyclic inhibitors of rho kinase |
| US20090318485A1 (en) * | 2006-07-20 | 2009-12-24 | Kalypsys, Inc. | Novel inhibitors of rho kinase |
| KR20090057223A (ko) | 2006-07-31 | 2009-06-04 | 센주 세이야꾸 가부시키가이샤 | 아미드 화합물을 함유하는 수성 액제 |
| EP2068878B1 (en) | 2006-09-20 | 2019-04-10 | Aerie Pharmaceuticals, Inc. | Rho kinase inhibitors |
| US20110039893A1 (en) * | 2006-10-11 | 2011-02-17 | Takeda Pharmaceutical Company Limited | Gsk-3beta inhibitor |
| US8949825B1 (en) | 2006-10-17 | 2015-02-03 | Manageiq, Inc. | Enforcement of compliance policies in managed virtual systems |
| WO2008049000A2 (en) | 2006-10-18 | 2008-04-24 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
| WO2008049919A2 (en) | 2006-10-26 | 2008-05-02 | Devgen N.V. | Rho kinase inhibitors |
| US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
| WO2008079945A2 (en) | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
| AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
| CN101578266B (zh) | 2006-12-27 | 2013-10-30 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹啉和异喹啉酮衍生物 |
| JP5405314B2 (ja) | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノロン誘導体 |
| MY155279A (en) | 2006-12-27 | 2015-09-30 | Sanofi Aventis | Substituted isoquinoline and isoquinolinone derivatives |
| MY148514A (en) | 2006-12-27 | 2013-04-30 | Sanofi Aventis | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives |
| JP5405316B2 (ja) | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノリン誘導体 |
| MY148902A (en) | 2006-12-27 | 2013-06-14 | Sanofi Aventis | Substituted isoquinolines and their use as rho-kinase inhibitors |
| JP5421783B2 (ja) | 2006-12-27 | 2014-02-19 | サノフイ | Ｒｈｏキナーゼ阻害剤としての置換イソキノロン及びイソキノリノン誘導体 |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| US8415372B2 (en) | 2007-02-27 | 2013-04-09 | Asahi Kasei Pharma Corporation | Sulfonamide compound |
| JP2010523689A (ja) | 2007-04-10 | 2010-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメティックス、その製造方法、医薬組成物及びその使用 |
| WO2009006567A2 (en) | 2007-07-05 | 2009-01-08 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| PL2217572T3 (pl) * | 2007-11-16 | 2014-04-30 | Vertex Pharma | Modulatory izochinolinowe transporterów zawierających kasetę wiążącą ATP |
| US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| JP2012500216A (ja) | 2008-08-15 | 2012-01-05 | エヌサーティー・ファーマシューティカルズ，エルエルシー | 治療薬剤としての、ｓ−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤 |
| EP3828172A1 (en) | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| AU2010261206B2 (en) | 2009-06-19 | 2015-10-08 | D. Western Therapeutics Institute, Inc. | Substituted isoquinoline derivative |
| WO2011085351A2 (en) * | 2010-01-11 | 2011-07-14 | The Johns Hopkins University | Method of treating kcnq related disorders |
| FR2961694B1 (fr) | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
| WO2012030944A2 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Quinoline and isoquinoline compounds and methods of use thereof |
| EP2637684A4 (en) | 2010-11-08 | 2014-05-07 | Healor Ltd | BUFFERED OPHTHALMIC COMPOSITIONS AND USER METHOD THEREFOR |
| TW202446398A (zh) | 2011-02-04 | 2024-12-01 | 日商興和股份有限公司 | 具眼壓下降作用之醫藥 |
| JP2013035802A (ja) | 2011-08-10 | 2013-02-21 | D Western Therapeutics Institute Inc | 緑内障又は高眼圧症の予防又は治療剤 |
| EP2671883A1 (en) | 2012-06-05 | 2013-12-11 | Bioprojet | New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands |
| JP2014019650A (ja) | 2012-07-13 | 2014-02-03 | Santen Pharmaceut Co Ltd | スルホンアミド化合物とタフルプロストの組み合わせ |
| JP2015529651A (ja) * | 2012-08-01 | 2015-10-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | α７ニコチン性アセチルコリン受容体モジュレーターおよびそれらの使用−Ｉ |
| CN105051005B (zh) * | 2012-10-12 | 2017-06-13 | 武田药品工业株式会社 | 环丙胺化合物及其用途 |
| CA2905089C (en) | 2013-03-15 | 2023-06-13 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds for the treatment of ocular diseases |
| CN106817900A (zh) | 2014-07-17 | 2017-06-09 | 默克专利有限公司 | 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途 |
| WO2016123627A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
| US9770466B2 (en) | 2015-07-02 | 2017-09-26 | Veloce Biopharma, Llc | Ophthalmic composition and methods of use |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| EP3500251A4 (en) | 2016-08-19 | 2020-04-08 | Aerie Pharmaceuticals, Inc. | BETA AMINO ISOCHINOLINYL AMIDE COMPOUNDS |
| BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
| CA3057872A1 (en) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
| AU2019245390B2 (en) | 2018-03-30 | 2022-02-17 | Alcon Inc. | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof |
| WO2020056345A1 (en) * | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
-
2018
- 2018-03-30 CA CA3057872A patent/CA3057872A1/en active Pending
- 2018-03-30 KR KR1020197031763A patent/KR20190135027A/ko not_active Withdrawn
- 2018-03-30 BR BR112019020078A patent/BR112019020078A2/pt not_active Application Discontinuation
- 2018-03-30 SG SG11201908179U patent/SG11201908179UA/en unknown
- 2018-03-30 WO PCT/US2018/025494 patent/WO2018183911A1/en unknown
- 2018-03-30 AU AU2018243687A patent/AU2018243687C1/en active Active
- 2018-03-30 EP EP18776337.0A patent/EP3609871A4/en active Pending
- 2018-03-30 JP JP2019553272A patent/JP2020515583A/ja active Pending
- 2018-03-30 MX MX2019011784A patent/MX2019011784A/es unknown
- 2018-03-30 CN CN201880021623.3A patent/CN110506037A/zh active Pending
- 2018-03-30 US US15/941,993 patent/US10858339B2/en active Active
-
2020
- 2020-07-22 US US16/936,257 patent/US11312700B2/en active Active
- 2020-10-06 AU AU2020250183A patent/AU2020250183A1/en not_active Abandoned
-
2022
- 2022-04-18 US US17/722,832 patent/US12018012B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190135027A (ko) | 2019-12-05 |
| US11312700B2 (en) | 2022-04-26 |
| US20210002253A1 (en) | 2021-01-07 |
| US12018012B2 (en) | 2024-06-25 |
| AU2018243687A1 (en) | 2019-09-26 |
| AU2018243687B2 (en) | 2020-07-09 |
| EP3609871A1 (en) | 2020-02-19 |
| WO2018183911A1 (en) | 2018-10-04 |
| US10858339B2 (en) | 2020-12-08 |
| CA3057872A1 (en) | 2018-10-04 |
| AU2020250183A1 (en) | 2020-11-05 |
| AU2018243687C1 (en) | 2020-12-24 |
| CN110506037A (zh) | 2019-11-26 |
| MX2019011784A (es) | 2019-11-18 |
| EP3609871A4 (en) | 2021-01-06 |
| US20180327381A1 (en) | 2018-11-15 |
| JP2020515583A (ja) | 2020-05-28 |
| BR112019020078A2 (pt) | 2020-04-28 |
| US20230130470A1 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201909963YA (en) | Methods for treating dravet syndrome | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201909303TA (en) | Point of delivery cold slurry generation | |
| SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| SG11201407372UA (en) | Nampt inhibitors | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201811655SA (en) | Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation | |
| SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201907153RA (en) | Topical formulations and methods |